Assessing PROMIS Pain Measures Across Various Disease Durations in IBM Patients from the INSPIRE IBM Trial


Clinical Trials

Poster Number: M235


Pola Gaid, BS, University of California, Irvine, Marie Wencel, BS, UCI Health, Namita Goyal, MD, UCI Health, Miriam Freimer, MD, Ohio State University, Olimpia Carbunar, MD, University of Miami Health Systems, Mazen Dimachkie, MD, University of Kansas Medical Center, Colin Quinn, MD, University of Pennsylvania, Thomas Lloyd, MD, PhD, Johns Hopkins University, Conrad Weihl, MD, PhD, Washington University in Saint Louis, Aziz Shaibani, MD, Nerve and Muscle Center of Texas, Tahseen Mozaffar, MD, UCI Health

OBJECTIVE: To evaluate and compare the PROMIS Pain Interference and PROMIS Pain Intensity scores among Inclusion Body Myositis (IBM) patients enrolled in the INSPIRE IBM trial, considering varying disease durations since symptom onset.

BACKGROUND: Inclusion body myositis (IBM) is a common muscular disorder in individuals over the age of 40 years, characterized by progressive muscle weakness, with some patients reporting pain as a prominent symptom, impacting their activities of daily living. Pain remains underrecognized and poorly understood in IBM patients. PROMIS pain measures (Pain intensity and Pain interference) provides an opportunity to explore patients’ pain perceptions at varying disease durations since symptom onset.

DESIGN/METHODS: INSPIRE-IBM is a prospective longitudinal natural history study in 150 subjects with Inclusion Body Myositis, being evaluated across 13 different US sites. This abstract will present and analyze pain symptoms reported in this study in the patients currently enrolled in the INSPIRE IBM trial. These patients will be stratified based on the duration of symptom onset within the first 10-year timeframe. PROMIS Pain Interference and Pain Intensity questionnaires were employed to assess and compare pain experiences across these subgroups. Additionally, the patients’ medical history will be considered to better discern the source of pain, differentiating between IBM-related causes and other medical factors.

RESULTS/CONCLUSION: Analysis will be done once enrollment closes in January 2024 when all patients have completed their baseline visit. Results from the baseline visit will be analyzed and presented.